JP2024515829A5 - - Google Patents
Info
- Publication number
- JP2024515829A5 JP2024515829A5 JP2023566514A JP2023566514A JP2024515829A5 JP 2024515829 A5 JP2024515829 A5 JP 2024515829A5 JP 2023566514 A JP2023566514 A JP 2023566514A JP 2023566514 A JP2023566514 A JP 2023566514A JP 2024515829 A5 JP2024515829 A5 JP 2024515829A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- degrees
- pharmaceutically acceptable
- acceptable salt
- including endpoints
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025074660A JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181743P | 2021-04-29 | 2021-04-29 | |
| US63/181,743 | 2021-04-29 | ||
| US202163197025P | 2021-06-04 | 2021-06-04 | |
| US63/197,025 | 2021-06-04 | ||
| US202163210810P | 2021-06-15 | 2021-06-15 | |
| US63/210,810 | 2021-06-15 | ||
| US202163239096P | 2021-08-31 | 2021-08-31 | |
| US63/239,096 | 2021-08-31 | ||
| US202163285812P | 2021-12-03 | 2021-12-03 | |
| US63/285,812 | 2021-12-03 | ||
| US202163289520P | 2021-12-14 | 2021-12-14 | |
| US202163289506P | 2021-12-14 | 2021-12-14 | |
| US63/289,520 | 2021-12-14 | ||
| US63/289,506 | 2021-12-14 | ||
| US202263298601P | 2022-01-11 | 2022-01-11 | |
| US63/298,601 | 2022-01-11 | ||
| PCT/US2022/026920 WO2022232504A1 (en) | 2021-04-29 | 2022-04-29 | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025074660A Division JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515829A JP2024515829A (ja) | 2024-04-10 |
| JP2024515829A5 true JP2024515829A5 (https=) | 2025-05-09 |
Family
ID=81748925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566514A Pending JP2024515829A (ja) | 2021-04-29 | 2022-04-29 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
| JP2025074660A Pending JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025074660A Pending JP2025111701A (ja) | 2021-04-29 | 2025-04-28 | 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240216395A1 (https=) |
| EP (1) | EP4329770A1 (https=) |
| JP (2) | JP2024515829A (https=) |
| KR (1) | KR20240006026A (https=) |
| AU (1) | AU2022266680A1 (https=) |
| BR (1) | BR112023022264A2 (https=) |
| CA (1) | CA3218072A1 (https=) |
| IL (1) | IL307991A (https=) |
| MX (1) | MX2023012727A (https=) |
| TW (1) | TW202308654A (https=) |
| WO (1) | WO2022232504A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
| CA3103421A1 (en) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| MX2021006985A (es) * | 2018-12-14 | 2021-09-08 | Praxis Prec Medicines Inc | Metodos para el tratamiento de la depresión. |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| IL315023A (en) * | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
-
2022
- 2022-04-29 WO PCT/US2022/026920 patent/WO2022232504A1/en not_active Ceased
- 2022-04-29 AU AU2022266680A patent/AU2022266680A1/en active Pending
- 2022-04-29 KR KR1020237040558A patent/KR20240006026A/ko active Pending
- 2022-04-29 EP EP22724335.9A patent/EP4329770A1/en active Pending
- 2022-04-29 CA CA3218072A patent/CA3218072A1/en active Pending
- 2022-04-29 MX MX2023012727A patent/MX2023012727A/es unknown
- 2022-04-29 TW TW111116469A patent/TW202308654A/zh unknown
- 2022-04-29 IL IL307991A patent/IL307991A/en unknown
- 2022-04-29 BR BR112023022264A patent/BR112023022264A2/pt unknown
- 2022-04-29 US US18/557,691 patent/US20240216395A1/en active Pending
- 2022-04-29 JP JP2023566514A patent/JP2024515829A/ja active Pending
-
2025
- 2025-04-28 JP JP2025074660A patent/JP2025111701A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515829A5 (https=) | ||
| CN108721265B (zh) | 通过给予秋水仙碱衍生物治疗或预防心血管事件 | |
| JP2021527092A5 (https=) | ||
| JP2024515830A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| JP2020534270A5 (https=) | ||
| JPH06102622B2 (ja) | 肥満の治療 | |
| JP2022533968A5 (https=) | ||
| JP2022502500A5 (https=) | ||
| JP2024510436A5 (https=) | ||
| JP2022550919A5 (https=) | ||
| JP2023520469A5 (https=) | ||
| Gohil | Multiple sclerosis: progress, but no cure | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2023509698A5 (https=) | ||
| Kooybaran et al. | Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib | |
| JP2024523559A5 (https=) | ||
| JP2023553253A5 (https=) | ||
| JP2024520132A5 (https=) | ||
| JP2023549849A5 (https=) | ||
| JP2017508737A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2025509278A5 (https=) | ||
| JP2023531930A5 (https=) |